A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
- Conditions
- COPDCOPD Exacerbation
- Interventions
- Registration Number
- NCT04320342
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Brief Summary
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
- Detailed Description
This is a phase III, multinational, multicenter, randomized, double-blind active controlled 2-arm parallel group study to compare efficacy, safety, and tolerability of CHF 5993 pMDI with CHF 1535 pMDI with respect to lung function, incidence of moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes.
After screening, eligible subjects will enter 2-week run-in period using their regular COPD maintenance therapies after which they will be randomized to one of 2 study treatment groups. Following randomization, subjects will be assessed after 4 weeks then at 6-week intervals thereafter for a period of 52 weeks. A follow-up safety phone call will be performed a week after the last clinic visit. A subset of subjects consenting to participate in the pharmacokinetic substudy will undergo additional assessments (totaling 3 visits) during the scheduled study visits.
During the study, daily symptoms, rescue medication use and compliance with the study drug will be recorded via a subject electronic diary. Subject concomitant medications, adverse events, and healthcare resource utilization will be assessed and recorded throughout the study. At intermittent study visits, subjects will undergo vital signs examinations including weight, spirometry measurements, and 12-lead ECG. Symptoms and COPD health status will be assessed through disease specific questionnaires. Routine hematology, blood chemistry, and serum pregnancy testing will be performed before enrollment and at end of study.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 3433
-
Signed and dated written informed consent must be obtained prior to initiating any study-related procedures
-
Outpatient
-
Male or female subjects aged ≥40 years
-
Female subjects:
- WOCBP fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signing of the informed consent form and until the follow-up contact or ii. WOCBP with non-fertile male partners (contraception is not required in this case).
- Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile as per definitions given in Appendix 5). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges)
-
COPD diagnosis for at least 12 months before the screening visit in accordance with the definition by the GOLD 2020 Report
-
Current or ex-smokers who quit smoking at least 6 months prior to screening with a smoking history of at least 10 pack-years [pack-years = (number of cigarettes per day x number of years)/20]
-
COPD Assessment Test (CAT) score ≥10
-
A pre- and post-bronchodilator FEV1/FVC ratio <0.70 at screening
-
A post-bronchodilator FEV1 <50% predicted normal at screening and a documented history of ≥1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator FEV1 ≥50% and <80% of predicted normal at screening and a documented history of ≥2 moderate COPD exacerbations or ≥1 severe COPD exacerbation in the previous 12 months
-
Subjects receiving daily inhaled maintenance therapy for their COPD, at a stable dose for at least 3 months prior to the screening and randomization visits
-
Documentation (including imagery and report) of chest x-ray (CXR) or CT scan performed within 6 months prior to the screening visit, without evidence of significant abnormalities (other than those related to the presence of COPD).
-
A cooperative attitude and ability to demonstrate correct use of the pMDI inhalers and eDiary.
-
Female subjects who are pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating
-
Subjects using the following medications prior to the screening visit and during the run-in period:
- Systemic/oral/parenteral corticosteroids in the prior 4 weeks
- Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) or COPD exacerbation in the prior 4 weeks
- Any long-term chronic maintenance use of antibiotic treatment in the prior 4 weeks
- Oral xanthine derivatives (e.g. theophylline) in the prior 7 days
-
A moderate or severe COPD exacerbation or a respiratory tract infection (e.g., pneumonia) that has not resolved ≤14 days prior to the screening visit or during the run-in period
-
Current treatment with non-cardioselective β-blockers
-
Requirement of long term (> 15 hours daily) oxygen therapy
-
Known respiratory disorders other than COPD which may impact the efficacy of the study drug according to investigator's judgement.
-
Lung transplant surgery or lung volume reduction surgery (subjects with lung volume reduction surgery are excluded if the procedure was performed within 1 year before the Screening visit)
-
Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator, would prevent use of anticholinergic agents
-
History of hypersensitivity to M3 receptor antagonists, β2 agonists, corticosteroids or any of the excipients contained in any of the study drugs used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator's judgement
-
Subject has severe, acute or uncontrolled cardiovascular condition (such as but not limited to unstable ischemic heart disease, NYHA Class IV, left ventricular failure, acute myocardial infarction or unstable angina) in the last 6 months
-
An abnormal and clinically significant 12-lead ECG at either the screening or randomization visit. This is characterized as but not limited to any of the following findings:
- Atrial fibrillation (AF) with rapid ventricular response > 120 bpm
- Ventricular tachycardias (sustained, non-sustained [>3 up to 30 sec])
- Evidence of Mobitz Type II second degree or third-degree atrioventricular block
- Prolonged QTcF (>450ms for males, or >470ms for females). This criterion is not applicable for subjects with a pacemaker or permanent AF.
-
Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement
-
Unstable or uncontrolled concurrent disease which may impact the efficacy or safety of the study drug or the subject's participation in the study according to investigator's judgment
-
Malignancy that has not been in complete remission for at least 1 year or any untreated localized carcinomas
-
History of alcohol abuse and/or substance/drug abuse within 12 months prior to the screening visit
-
Receipt of any other investigational drug within 1 month or 5 half-lives (whichever is greater) prior to the screening visit or have been previously randomized in this trial, or are currently participating in another clinical trial
-
Currently in the acute phase of a pulmonary rehabilitation program within 4 weeks before the screening visit or planning to enroll in the acute phase of such a program during the study. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded
-
Mentally or legally incapacitated, or subjects incarcerated as a result of an official or judicial order
-
Major surgery in the 3 months prior to the screening visit or have a planned surgery during the trial
-
Non-satisfactory compliance with the eDiary (<65% or >135%) during the run-in period
-
Subjects requiring the use of spacer device or nebulizer for administration of maintenance COPD therapies.
-
Veins unsuitable for repeat venipuncture
-
Blood donation or blood loss (≥450mL) in the 4 weeks before randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BDP/FF/GB - CHF 5993 Glycopyrronium Bromide Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler BDP/FF/GB - CHF 5993 Formoterol Fumarate Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler BDP/FF - CHF 1535 Formoterol Fumarate Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler BDP/FF/GB - CHF 5993 Beclomethasone Dipropionate Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler BDP/FF - CHF 1535 Beclomethasone Dipropionate Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler
- Primary Outcome Measures
Name Time Method Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28 Week 28
- Secondary Outcome Measures
Name Time Method Change from baseline in the SGRQ total score and domain scores at each designated clinic visit Week 4, Week 10, Week 28, Week 40, & Week 52 Rate of moderate and severe COPD exacerbations over 52 weeks of treatment 52-week treatment period Annualized rate of moderate and severe COPD exacerbations as observed during the 52-week study treatment period.
Rate of severe COPD exacerbations over 52 weeks of treatment 52-week treatment period Annualized rate of severe COPD exacerbations as observed during 52-week treatment period
Time to first severe COPD exacerbation 52-week treatment period Saint George's Respiratory Questionnaire (SGRQ) response (a decrease from baseline in total score ≥4) at designated clinic visits Week 4, Week 10, Week 28, Week 40, & Week 52 Change from pre-dose to 2-hour post-dose morning FVC at designated clinic visits Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 Change from baseline to each inter-visit period in the average E-RS total score and domain scores Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 Change from baseline (defined as the 2-week run-in period prior to randomization) in the average E-RS total score and E-RS domain scores for the period of time between designated clinic visits.
Change from baseline in COPD Assessment Test (CAT) score at designated clinic visit Week 4, Week 10, Week 28, Week 40, & Week 52 The CAT is composed of 8 questions to measure the impact of COPD on daily life, which are scored from 0 to 5 with higher scores reflecting greater impact.
CAT response (decrease from baseline ≥2 points) at designated clinic visits Week 4, Week 10, Week 28, Week 40, & Week 52 Modified Medical Research Council (mMRC) dyspnea scale at designated clinic visits Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 Descriptive statistics of the mMRC dyspnea scale score at designated clinic visits. The mMRC dyspnea scale is graded from 0 to 4, with higher grades reflecting greater severity.
Change from baseline in health-related quality of life (decrease from baseline in total SGRQ score ≥4) over 52 weeks of treatment. 52-week treatment period Change from baseline in pre-dose morning FEV1 at designated clinic visits Week 4, Week 10, Week 40, & Week 52 Change from baseline in 2-hour post-dose morning FEV1 at Week 28 Week 28 Change from baseline in 2-hour post-dose morning FEV1 designated clinic visits Day 1, Week 4, Week 10, Week 40, & Week 52 FEV1 response (change from baseline in pre-dose morning FEV1 ≥100ml) at designated clinic visits Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 Time to first moderate or severe COPD exacerbation 52-week treatment period Change from baseline to each inter-visit period in the average use of rescue medication (number of puffs/day) Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 Change from baseline (defined as the 2-week run-in period prior to randomization) in the average number of puffs per day of rescue medication for each inter-visit period (defined as the period of time between designated clinic visits).
Change from baseline in pre-dose morning Forced Vital Capacity (FVC) at designated clinic visits Week 4, Week 10, Week 28, Week 40, & Week 52 Change from baseline in 2-hour post-dose morning FVC at designated clinic visits Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 Change from baseline (defined as the pre-dose value on Day 1) in 2-hour post-dose morning FVC at designated clinic visits
Change from pre-dose to 2-hour post-dose morning FEV1 at designated clinic visits Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 Change from baseline to each inter-visit period in the percentage of days without intake of rescue medication Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 Change from baseline (defined as the 2-week run-in period prior to randomization) to each inter-visit period (defined as the period of time between designated clinic visits) in percentage of days without rescue medication
Trial Locations
- Locations (436)
Chiesi Clinical Trial Site 100113
🇧🇬Ruse, Bulgaria
Chiesi Clinical Trial Site 840206
🇺🇸Montgomery, Alabama, United States
Chiesi Clinical Trial Site 840144
🇺🇸Westminster, California, United States
Chiesi Clinical Trial Site 840229
🇺🇸Boulder, Colorado, United States
Chiesi Clinical Trial Site 840310
🇺🇸Brooksville, Florida, United States
Chiesi Clinical Trial Site 840272
🇺🇸Coral Gables, Florida, United States
Chiesi Clinical Trial Site 484108
🇲🇽Tlalpan, Mexico
Chiesi Clinical Trial Site 616125
🇵🇱Białystok, Poland
Chiesi Clinical Trial Site 840385
🇺🇸Miami Lakes, Florida, United States
Chiesi Clinical Trial Site 840353
🇺🇸Miami Lakes, Florida, United States
Chiesi Clinical Trial Site 840372
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840341
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840237
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840262
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840202
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840137
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840289
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840148
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840377
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840387
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840326
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840346
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840312
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840261
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840280
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840175
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840347
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840205
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840247
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840178
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840381
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840239
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840355
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840388
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840292
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840275
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840122
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840352
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840235
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840243
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840360
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840244
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840257
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840380
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840382
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840367
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840162
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840166
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840370
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840392
🇺🇸Miami, Florida, United States
Chiesi Clinical Trial Site 840140
🇺🇸Mount Dora, Florida, United States
Chiesi Clinical Trial Site 840263
🇺🇸New Port Richey, Florida, United States
Chiesi Clinical Trial Site 840161
🇺🇸North Miami Beach, Florida, United States
Chiesi Clinical Trial Site 840132
🇺🇸North Miami, Florida, United States
Chiesi Clinical Trial Site 840255
🇺🇸Orlando, Florida, United States
Chiesi Clinical Trial Site 840110
🇺🇸Orlando, Florida, United States
Chiesi Clinical Trial Site 840125
🇺🇸Orlando, Florida, United States
Chiesi Clinical Trial Site 840121
🇺🇸Palmetto Bay, Florida, United States
Chiesi Clinical Trial Site 840196
🇺🇸Pembroke Pines, Florida, United States
Chiesi Clinical Trial Site 840198
🇺🇸Pembroke Pines, Florida, United States
Chiesi Clinical Trial Site 840363
🇺🇸Plantation, Florida, United States
Chiesi Clinical Trial Site 840371
🇺🇸Plantation, Florida, United States
Chiesi Clinical Trial Site 840252
🇺🇸Pompano Beach, Florida, United States
Chiesi Clinical Trial Site 840105
🇺🇸Port Charlotte, Florida, United States
Chiesi Clinical Trial Site 840291
🇺🇸Saint Petersburg, Florida, United States
Chiesi Clinical Trial Site 840294
🇺🇸Sarasota, Florida, United States
Chiesi Clinical Trial Site 840313
🇺🇸Tampa, Florida, United States
Chiesi Clinical Trial Site 840356
🇺🇸Tampa, Florida, United States
Chiesi Clinical Trial Site 840379
🇺🇸Tampa, Florida, United States
Chiesi Clinical Trial Site 840131
🇺🇸Tampa, Florida, United States
Chiesi Clinical Trial Site 840324
🇺🇸Tampa, Florida, United States
Chiesi Clinical Trial Site 840309
🇺🇸Tampa, Florida, United States
Chiesi Clinical Trial Site 840210
🇺🇸The Villages, Florida, United States
Chiesi Clinical Trial Site 840129
🇺🇸Winter Park, Florida, United States
Chiesi Clinical Trial Site 840223
🇺🇸Adairsville, Georgia, United States
Chiesi Clinical Trial Site 840218
🇺🇸Columbus, Georgia, United States
Chiesi Clinical Trial Site 840414
🇺🇸Columbus, Georgia, United States
Chiesi Clinical Trial Site 840437
🇺🇸Cordele, Georgia, United States
Chiesi Clinical Trial Site 840390
🇺🇸Lawrenceville, Georgia, United States
Chiesi Clinical Trial Site 840227
🇺🇸Lawrenceville, Georgia, United States
Chiesi Clinical Trial Site 840297
🇺🇸Berlin, New Jersey, United States
Chiesi Clinical Trial Site 840333
🇺🇸Toms River, New Jersey, United States
Chiesi Clinical Trial Site 840330
🇺🇸Binghamton, New York, United States
Chiesi Clinical Trial Site 840128
🇺🇸Bronx, New York, United States
Chiesi Clinical Trial Site 840397
🇺🇸Brooklyn, New York, United States
Chiesi Clinical Trial Site 840254
🇺🇸Buffalo, New York, United States
Chiesi Clinical Trial Site 840307
🇺🇸Buffalo, New York, United States
Chiesi Clinical Trial Site 840368
🇺🇸Flushing, New York, United States
Chiesi Clinical Trial Site 840362
🇺🇸New Windsor, New York, United States
Chiesi Clinical Trial Site 840215
🇺🇸Charlotte, North Carolina, United States
Chiesi Clinical Trial Site 840366
🇺🇸Charlotte, North Carolina, United States
Chiesi Clinical Trial Site 840158
🇺🇸Charlotte, North Carolina, United States
Chiesi Clinical Trial Site 840409
🇺🇸Denver, North Carolina, United States
Chiesi Clinical Trial Site 840403
🇺🇸Durham, North Carolina, United States
Chiesi Clinical Trial Site 840428
🇺🇸Gastonia, North Carolina, United States
Chiesi Clinical Trial Site 840236
🇺🇸Huntersville, North Carolina, United States
Chiesi Clinical Trial Site 840259
🇺🇸Monroe, North Carolina, United States
Chiesi Clinical Trial Site 840440
🇺🇸Morgantown, North Carolina, United States
Chiesi Clinical Trial Site 840194
🇺🇸New Bern, North Carolina, United States
Chiesi Clinical Trial Site 840120
🇺🇸Raleigh, North Carolina, United States
Chiesi Clinical Trial Site 840438
🇺🇸Raleigh, North Carolina, United States
Chiesi Clinical Trial Site 840429
🇺🇸Raleigh, North Carolina, United States
Chiesi Clinical Trial Site 840112
🇺🇸Rocky Mount, North Carolina, United States
Chiesi Clinical Trial Site 840135
🇺🇸Shelby, North Carolina, United States
Chiesi Clinical Trial Site 840189
🇺🇸Wilmington, North Carolina, United States
Chiesi Clinical Trial Site 840412
🇺🇸Winston-Salem, North Carolina, United States
Chiesi Clinical Trial Site 840445
🇺🇸Akron, Ohio, United States
Chiesi Clinical Trial Site 840104
🇺🇸Cincinnati, Ohio, United States
Chiesi Clinical Trial Site 840357
🇺🇸Cincinnati, Ohio, United States
Chiesi Clinical Trial Site 840124
🇺🇸Columbus, Ohio, United States
Chiesi Clinical Trial Site 840426
🇺🇸Dayton, Ohio, United States
Chiesi Clinical Trial Site 840302
🇺🇸Kettering, Ohio, United States
Chiesi Clinical Trial Site 840233
🇺🇸Maumee, Ohio, United States
Chiesi Clinical Trial Site 840167
🇺🇸Middleburg Heights, Ohio, United States
Chiesi Clinical Trial Site 840157
🇺🇸Toledo, Ohio, United States
Chiesi Clinical Trial Site 840203
🇺🇸Medford, Oregon, United States
Chiesi Clinical Trial Site 840300
🇺🇸Beaver, Pennsylvania, United States
Chiesi Clinical Trial Site 840308
🇺🇸DuBois, Pennsylvania, United States
Chiesi Clinical Trial Site 840156
🇺🇸Jenkintown, Pennsylvania, United States
Chiesi Clinical Trial Site 840327
🇺🇸Pittsburgh, Pennsylvania, United States
Chiesi Clinical Trial Site 840418
🇺🇸Scotland, Pennsylvania, United States
Chiesi Clinical Trial Site 840419
🇺🇸Smithfield, Pennsylvania, United States
Chiesi Clinical Trial Site 840450
🇺🇸Cranston, Rhode Island, United States
Chiesi Clinical Trial Site 840332
🇺🇸Cumberland, Rhode Island, United States
Chiesi Clinical Trial Site 840222
🇺🇸Anderson, South Carolina, United States
Chiesi Clinical Trial Site 840435
🇺🇸Anderson, South Carolina, United States
Chiesi Clinical Trial Site 840431
🇺🇸Charleston, South Carolina, United States
Chiesi Clinical Trial Site 840334
🇺🇸Columbia, South Carolina, United States
Chiesi Clinical Trial Site 840146
🇺🇸Cypress, Texas, United States
Chiesi Clinical Trial Site 840413
🇺🇸Dallas, Texas, United States
Chiesi Clinical Trial Site 840106
🇺🇸Union, South Carolina, United States
Chiesi Clinical Trial Site 840295
🇺🇸West Columbia, South Carolina, United States
Chiesi Clinical Trial Site 840398
🇺🇸Rapid City, South Dakota, United States
Chiesi Clinical Trial Site 840361
🇺🇸Nashville, Tennessee, United States
Chiesi Clinical Trial Site 840271
🇺🇸Tullahoma, Tennessee, United States
Chiesi Clinical Trial Site 840101
🇺🇸Baytown, Texas, United States
Chiesi Clinical Trial Site 840114
🇺🇸Boerne, Texas, United States
Chiesi Clinical Trial Site 840408
🇺🇸Humble, Texas, United States
Chiesi Clinical Trial Site 840102
🇺🇸Katy, Texas, United States
Chiesi Clinical Trial Site 840274
🇺🇸Katy, Texas, United States
Chiesi Clinical Trial Site 840305
🇺🇸Chattanooga, Tennessee, United States
Chiesi Clinical Trial Site 840351
🇺🇸Franklin, Tennessee, United States
Chiesi Clinical Trial Site 840306
🇺🇸Johnson City, Tennessee, United States
Chiesi Clinical Trial Site 840171
🇺🇸Knoxville, Tennessee, United States
Chiesi Clinical Trial Site 840284
🇺🇸Houston, Texas, United States
Chiesi Clinical Trial Site 840411
🇺🇸Houston, Texas, United States
Chiesi Clinical Trial Site 840389
🇺🇸Houston, Texas, United States
Chiesi Clinical Trial Site 840185
🇺🇸Houston, Texas, United States
Chiesi Clinical Trial Site 840176
🇺🇸North Richland Hills, Texas, United States
Chiesi Clinical Trial Site 840283
🇺🇸Pearland, Texas, United States
Chiesi Clinical Trial Site 840191
🇺🇸San Antonio, Texas, United States
Chiesi Clinical Trial Site 840320
🇺🇸San Antonio, Texas, United States
Chiesi Clinical Trial Site 840410
🇺🇸San Antonio, Texas, United States
Chiesi Clinical Trial Site 840231
🇺🇸Sherman, Texas, United States
Chiesi Clinical Trial Site 840396
🇺🇸Sherman, Texas, United States
Chiesi Clinical Trial Site 840394
🇺🇸Splendora, Texas, United States
Chiesi Clinical Trial Site 616112
🇵🇱Wrocław, Poland
Chiesi Clinical Trial Site 616101
🇵🇱Zawadzkie, Poland
Chiesi Clinical Trial Site 840113
🇺🇸Leesburg, Florida, United States
Chiesi Clinical Trial Site 642103
🇷🇴Bucharest, Romania
Chiesi Clinical Trial Site 642113
🇷🇴Bucharest, Romania
Chiesi Clinical Trial Site 642108
🇷🇴Bucuresti, Romania
Chiesi Clinical Trial Site 642115
🇷🇴Caracal, Romania
Chiesi Clinical Trial Site 642111
🇷🇴Cluj-Napoca, Romania
Chiesi Clinical Trial Site 642105
🇷🇴Constanţa, Romania
Chiesi Clinical Trial Site 642110
🇷🇴Craiova, Romania
Chiesi Clinical Trial Site 642118
🇷🇴Craiova, Romania
Chiesi Clinical Trial Site 642101
🇷🇴Iaşi, Romania
Chiesi Clinical Trial Site 642114
🇷🇴Reșca, Romania
Chiesi Clinical Trial Site 642112
🇷🇴Satu Mare, Romania
Chiesi Clinical Trial Site 642116
🇷🇴Timişoara, Romania
Chiesi Clinical Trial Site 100132
🇧🇬Pleven, Bulgaria
Chiesi Clinical Trial Site 100101
🇧🇬Pleven, Bulgaria
Chiesi Clinical Trial Site 840433
🇺🇸Mobile, Alabama, United States
Chiesi Clinical Trial Site 616113
🇵🇱Grudziądz, Poland
Chiesi Clinical Trial Site 616116
🇵🇱Katowice, Poland
Chiesi Clinical Trial Site 616122
🇵🇱Kraków, Poland
Chiesi Clinical Trial Site 616106
🇵🇱Kraków, Poland
Chiesi Clinical Trial Site 616109
🇵🇱Kraków, Poland
Chiesi Clinical Trial Site 616118
🇵🇱Kraków, Poland
Chiesi Clinical Trial Site 100114
🇧🇬Vidin, Bulgaria
Chiesi Clinical Trial Site 203114
🇨🇿Praha, Czechia
Chiesi Clinical Trial Site 840186
🇺🇸Dothan, Alabama, United States
Chiesi Clinical Trial Site 616128
🇵🇱Olsztyn, Poland
Chiesi Clinical Trial Site 100100
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100110
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100112
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100116
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100117
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100130
🇧🇬Varna, Bulgaria
Chiesi Clinical Trial Site 124102
🇨🇦Burlington, Ontario, Canada
Chiesi Clinical Trial Site 124104
🇨🇦Sudbury, Ontario, Canada
Chiesi Clinical Trial Site 203109
🇨🇿Miroslav, Czechia
Chiesi Clinical Trial Site 100118
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100121
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 124105
🇨🇦Sherwood Park, Alberta, Canada
Chiesi Clinical Trial Site 100119
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100122
🇧🇬Veliko Tarnovo, Bulgaria
Chiesi Clinical Trial Site 100106
🇧🇬Vidin, Bulgaria
Chiesi Clinical Trial Site 124103
🇨🇦Edmonton, Alberta, Canada
Chiesi Clinical Trial Site 203107
🇨🇿Jindřichův Hradec, Czechia
Chiesi Clinical Trial Site 203115
🇨🇿Praha, Czechia
Chiesi Clinical Trial Site 100123
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100124
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100127
🇧🇬Sofia, Bulgaria
Chiesi Clinical Trial Site 100103
🇧🇬Stara Zagora, Bulgaria
Chiesi Clinical Trial Site 100107
🇧🇬Stara Zagora, Bulgaria
Chiesi Clinical Trial Site 124106
🇨🇦Trois-Rivières, Quebec, Canada
Chiesi Clinical Trial Site 203101
🇨🇿Brandýs Nad Labem, Czechia
Chiesi Clinical Trial Site 203116
🇨🇿Praha, Czechia
Chiesi Clinical Trial Site 203108
🇨🇿Strakonice, Czechia
Chiesi Clinical Trial Site 840258
🇺🇸Foley, Alabama, United States
Chiesi Clinical Trial Site 124100
🇨🇦Windsor, Ontario, Canada
Chiesi Clinical Trial Site 203112
🇨🇿Rokycany, Czechia
Chiesi Clinical Trial Site 348104
🇭🇺Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary
Chiesi Clinical Trial Site 348109
🇭🇺Nyiregyhaza, Szabolcs-Szatmár-Bereg, Hungary
Chiesi Clinical Trial Site 348105
🇭🇺Szombathely, Vas, Hungary
Chiesi Clinical Trial Site 348118
🇭🇺Debrecen, Hungary
Chiesi Clinical Trial Site 348112
🇭🇺Hajdúnánás, Hungary
Chiesi Clinical Trial Site 348116
🇭🇺Hatvan, Hungary
Chiesi Clinical Trial Site 348103
🇭🇺Monor, Hungary
Chiesi Clinical Trial Site 840279
🇺🇸Jasper, Alabama, United States
Chiesi Clinical Trial Site 203104
🇨🇿Teplice, Czechia
Chiesi Clinical Trial Site 203105
🇨🇿Tábor, Czechia
Chiesi Clinical Trial Site 203110
🇨🇿Varnsdorf, Czechia
Chiesi Clinical Trial Site 348121
🇭🇺Komló, BA, Hungary
Chiesi Clinical Trial Site 348122
🇭🇺Pécs, BA, Hungary
Chiesi Clinical Trial Site 348124
🇭🇺Csorna, GS, Hungary
Chiesi Clinical Trial Site 348126
🇭🇺Szolnok, JN, Hungary
Chiesi Clinical Trial Site 348107
🇭🇺Balassagyarmat, Nograd, Hungary
Chiesi Clinical Trial Site 348120
🇭🇺Gödöllő, Pest, Hungary
Chiesi Clinical Trial Site 348125
🇭🇺Sellye, Hungary
Chiesi Clinical Trial Site 484110
🇲🇽Tijuana, Baja California, Mexico
Chiesi Clinical Trial Site 484103
🇲🇽Cuauhtémoc, Cdmx, Mexico
Chiesi Clinical Trial Site 484113
🇲🇽Guadalajara, Jalisco, Mexico
Chiesi Clinical Trial Site 484100
🇲🇽Guadalajara, Jalisco, Mexico
Chiesi Clinical Trial Site 484102
🇲🇽Guadalajara, Jalisco, Mexico
Chiesi Clinical Trial Site 484104
🇲🇽Guadalajara, Jalisco, Mexico
Chiesi Clinical Trial Site 484106
🇲🇽Guadalajara, Jalisco, Mexico
Chiesi Clinical Trial Site 484112
🇲🇽Guadalajara, Jalisco, Mexico
Chiesi Clinical Trial Site 484115
🇲🇽Guadalupe, Jalisco, Mexico
Chiesi Clinical Trial Site 484107
🇲🇽Morelia, Michoacan, Mexico
Chiesi Clinical Trial Site 840350
🇺🇸Birmingham, Alabama, United States
Chiesi Clinical Trial Site 840249
🇺🇸Muscle Shoals, Alabama, United States
Chiesi Clinical Trial Site 840406
🇺🇸Chandler, Arizona, United States
Chiesi Clinical Trial Site 840402
🇺🇸Peoria, Arizona, United States
Chiesi Clinical Trial Site 616115
🇵🇱Toruń, Poland
Chiesi Clinical Trial Site 840349
🇺🇸Tucson, Arizona, United States
Chiesi Clinical Trial Site 840404
🇺🇸Covina, California, United States
Chiesi Clinical Trial Site 840209
🇺🇸Escondido, California, United States
Chiesi Clinical Trial Site 840427
🇺🇸La Palma, California, United States
Chiesi Clinical Trial Site 484101
🇲🇽Monterrey, Nuevo Leon, Mexico
Chiesi Clinical Trial Site 484111
🇲🇽Monterrey, Nuevo Leon, Mexico
Chiesi Clinical Trial Site 616127
🇵🇱Warszawa, Poland
Chiesi Clinical Trial Site 840358
🇺🇸Lomita, California, United States
Chiesi Clinical Trial Site 840173
🇺🇸Newport Beach, California, United States
Chiesi Clinical Trial Site 840208
🇺🇸Northridge, California, United States
Chiesi Clinical Trial Site 840364
🇺🇸Redding, California, United States
Chiesi Clinical Trial Site 840277
🇺🇸Northridge, California, United States
Chiesi Clinical Trial Site 484105
🇲🇽Chihuahua, Mexico
Chiesi Clinical Trial Site 840226
🇺🇸Sacramento, California, United States
Chiesi Clinical Trial Site 484116
🇲🇽Chihuahua, Mexico
Chiesi Clinical Trial Site 484109
🇲🇽Chihuahua, Mexico
Chiesi Clinical Trial Site 840107
🇺🇸San Diego, California, United States
Chiesi Clinical Trial Site 840373
🇺🇸Santa Ana, California, United States
Chiesi Clinical Trial Site 616126
🇵🇱Wrocław, Poland
Chiesi Clinical Trial Site 616119
🇵🇱Białystok, Poland
Chiesi Clinical Trial Site 840405
🇺🇸Sacramento, California, United States
Chiesi Clinical Trial Site 840164
🇺🇸Upland, California, United States
Chiesi Clinical Trial Site 840441
🇺🇸Aurora, Colorado, United States
Chiesi Clinical Trial Site 840268
🇺🇸Aventura, Florida, United States
Chiesi Clinical Trial Site 840192
🇺🇸Brandon, Florida, United States
Chiesi Clinical Trial Site 840174
🇺🇸West Covina, California, United States
Chiesi Clinical Trial Site 840399
🇺🇸Norwalk, Connecticut, United States
Chiesi Clinical Trial Site 616104
🇵🇱Wrocław, Poland
Chiesi Clinical Trial Site 840116
🇺🇸Altamonte Springs, Florida, United States
Chiesi Clinical Trial Site 840240
🇺🇸Chiefland, Florida, United States
Chiesi Clinical Trial Site 840304
🇺🇸Coral Gables, Florida, United States
Chiesi Clinical Trial Site 840153
🇺🇸Clearwater, Florida, United States
Chiesi Clinical Trial Site 840193
🇺🇸Cutler Bay, Florida, United States
Chiesi Clinical Trial Site 840311
🇺🇸Cutler Bay, Florida, United States
Chiesi Clinical Trial Site 840335
🇺🇸Cutler Bay, Florida, United States
Chiesi Clinical Trial Site 840141
🇺🇸Daytona Beach, Florida, United States
Chiesi Clinical Trial Site 840133
🇺🇸DeLand, Florida, United States
Chiesi Clinical Trial Site 840269
🇺🇸Doral, Florida, United States
Chiesi Clinical Trial Site 840354
🇺🇸Hialeah Gardens, Florida, United States
Chiesi Clinical Trial Site 840256
🇺🇸Hialeah Gardens, Florida, United States
Chiesi Clinical Trial Site 840303
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 616100
🇵🇱Gizycko, Poland
Chiesi Clinical Trial Site 616117
🇵🇱Ostrowiec, Poland
Chiesi Clinical Trial Site 840163
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 616105
🇵🇱Ostróda, Poland
Chiesi Clinical Trial Site 616123
🇵🇱Poznań, Poland
Chiesi Clinical Trial Site 616107
🇵🇱Poznań, Poland
Chiesi Clinical Trial Site 616110
🇵🇱Poznań, Poland
Chiesi Clinical Trial Site 616108
🇵🇱Rzeszów, Poland
Chiesi Clinical Trial Site 616114
🇵🇱Skierniewice, Poland
Chiesi Clinical Trial Site 616120
🇵🇱Skorzewo, Poland
Chiesi Clinical Trial Site 616102
🇵🇱Sosnowiec, Poland
Chiesi Clinical Trial Site 616111
🇵🇱Tarnów, Poland
Chiesi Clinical Trial Site 840165
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840238
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840265
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840241
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840253
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840184
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840267
🇺🇸Hialeah, Florida, United States
Chiesi Clinical Trial Site 840200
🇺🇸Kissimmee, Florida, United States
Chiesi Clinical Trial Site 840232
🇺🇸Lakeland, Florida, United States
Chiesi Clinical Trial Site 642119
🇷🇴Timişoara, Timis, Romania
Chiesi Clinical Trial Site 642109
🇷🇴Bacău, Romania
Chiesi Clinical Trial Site 642106
🇷🇴Bragadiru, Romania
Chiesi Clinical Trial Site 642117
🇷🇴Braşov, Romania
Chiesi Clinical Trial Site 840319
🇺🇸Miami Beach, Florida, United States
Chiesi Clinical Trial Site 616103
🇵🇱Łódź, Poland
Chiesi Clinical Trial Site 840393
🇵🇷Guaynabo, Puerto Rico
Chiesi Clinical Trial Site 642102
🇷🇴Oradea, Bihor, Romania
Chiesi Clinical Trial Site 642104
🇷🇴Cluj-Napoca, Cluj, Romania
Chiesi Clinical Trial Site 642120
🇷🇴Deva, Hunedoara, Romania
Chiesi Clinical Trial Site 642107
🇷🇴Bragadiru, Ilfov, Romania
Chiesi Clinical Trial Site 840328
🇺🇸Miami Lakes, Florida, United States
Chiesi Clinical Trial Site 840378
🇺🇸Miami Lakes, Florida, United States
Chiesi Clinical Trial Site 840288
🇺🇸Miami Lakes, Florida, United States
Chiesi Clinical Trial Site 840138
🇺🇸Rincon, Georgia, United States
Chiesi Clinical Trial Site 840383
🇺🇸Union City, Georgia, United States
Chiesi Clinical Trial Site 840108
🇺🇸Valparaiso, Indiana, United States
Chiesi Clinical Trial Site 840318
🇺🇸Council Bluffs, Iowa, United States
Chiesi Clinical Trial Site 840447
🇺🇸Baltimore, Maryland, United States
Chiesi Clinical Trial Site 840199
🇺🇸Westminster, Maryland, United States
Chiesi Clinical Trial Site 840214
🇺🇸Fall River, Massachusetts, United States
Chiesi Clinical Trial Site 840417
🇺🇸Stonecrest, Georgia, United States
Chiesi Clinical Trial Site 840365
🇺🇸Chicago Ridge, Illinois, United States
Chiesi Clinical Trial site 840250
🇺🇸North Dartmouth, Massachusetts, United States
Chiesi Clinical Trial Site 840400
🇺🇸Dearborn, Michigan, United States
Chiesi Clinical Trial Site 840321
🇺🇸Chicago, Illinois, United States
Chiesi Clinical Trial Site 840407
🇺🇸Hammond, Indiana, United States
Chiesi Clinical Trial Site 840451
🇺🇸Bangor, Maine, United States
Chiesi Clinical Trial Site 840376
🇺🇸Baltimore, Maryland, United States
Chiesi Clinical Trial Site 840325
🇺🇸Dearborn, Michigan, United States
Chiesi Clinical Trial Site 840207
🇺🇸Crowley, Louisiana, United States
Chiesi Clinical Trial Site 840436
🇺🇸Zachary, Louisiana, United States
Chiesi Clinical Trial Site 840322
🇺🇸New Bedford, Massachusetts, United States
Chiesi Clinical Trial Site 840338
🇺🇸Portsmouth, New Hampshire, United States
Chiesi Clinical Trial Site 840183
🇺🇸Farmington Hills, Michigan, United States
Chiesi Clinical Trial Site 840340
🇺🇸Flint, Michigan, United States
Chiesi Clinical Trial Site 840401
🇺🇸Flint, Michigan, United States
Chiesi Clinical Trial Site 840345
🇺🇸Novi, Michigan, United States
Chiesi Clinical Trial Site 840287
🇺🇸Southfield, Michigan, United States
Chiesi Clinical Trial Site 840415
🇺🇸Southfield, Michigan, United States
Chiesi Clinical Trial Site 840444
🇺🇸Fayette, Mississippi, United States
Chiesi Clinical Trial Site 840448
🇺🇸Ridgeland, Mississippi, United States
Chiesi Clinical Trial Site 840278
🇺🇸Chesterfield, Missouri, United States
Chiesi Clinical Trial Site 840155
🇺🇸Columbia, Missouri, United States
Chiesi Clinical Trial Site 840316
🇺🇸Richmond Heights, Missouri, United States
Chiesi Clinical Trial Site 840150
🇺🇸Saint Charles, Missouri, United States
Chiesi Clinical Trial Site 840282
🇺🇸Saint Louis, Missouri, United States
Chiesi Clinical Trial Site 840123
🇺🇸Saint Louis, Missouri, United States
Chiesi Clinical Trial Site 840142
🇺🇸Saint Louis, Missouri, United States
Chiesi Clinical Trial Site 840273
🇺🇸Missoula, Montana, United States
Chiesi Clinical Trial Site 840281
🇺🇸Lincoln, Nebraska, United States
Chiesi Clinical Trial Site 840329
🇺🇸Omaha, Nebraska, United States
Chiesi Clinical Trial Site 840213
🇺🇸Las Vegas, Nevada, United States
Chiesi Clinical Trial Site 840285
🇺🇸Las Vegas, Nevada, United States
Chiesi Clinical Trial Site 840299
🇺🇸Las Vegas, Nevada, United States
Chiesi Clinical Trial Site 840130
🇺🇸Columbia, South Carolina, United States
Chiesi Clinical Trial Site 840430
🇺🇸Columbia, South Carolina, United States
Chiesi Clinical Trial Site 840211
🇺🇸Fort Mill, South Carolina, United States
Chiesi Clinical Trial Site 840386
🇺🇸Mauldin, South Carolina, United States
Chiesi Clinical Trial Site 840182
🇺🇸Gaffney, South Carolina, United States
Chiesi Clinical Trial Site 840111
🇺🇸Greenville, South Carolina, United States
Chiesi Clinical Trial Site 840375
🇺🇸Spartanburg, South Carolina, United States
Chiesi Clinical Trial Site 840420
🇺🇸Lancaster, South Carolina, United States
Chiesi Clinical Trial Site 840100
🇺🇸Rock Hill, South Carolina, United States
Chiesi Clinical Trial Site 840224
🇺🇸Houston, Texas, United States
Chiesi Clinical Trial Site 840432
🇺🇸Kerrville, Texas, United States
Chiesi Clinical Trial Site 840160
🇺🇸Lampasas, Texas, United States
Chiesi Clinical Trial Site 840424
🇺🇸McAllen, Texas, United States
Chiesi Clinical Trial Site 840119
🇺🇸McKinney, Texas, United States
Chiesi Clinical Trial Site 840442
🇺🇸Nederland, Texas, United States
Chiesi Clinical Trial Site 840221
🇺🇸Sugar Land, Texas, United States
Chiesi Clinical Trial Site 840139
🇺🇸Tomball, Texas, United States
Chiesi Clinical Trial Site 840314
🇺🇸Tomball, Texas, United States
Chiesi Clinical Trial Site 840337
🇺🇸Colchester, Vermont, United States
Chiesi Clinical Trial Site 840264
🇺🇸Manassas, Virginia, United States
Chiesi Clinical Trial Site 100111
🇧🇬Lovech, Bulgaria
Chiesi Clinical Trial Site 840159
🇺🇸Richmond, Virginia, United States
Chiesi Clinical Trial Site 840425
🇺🇸Richmond, Virginia, United States
Chiesi Clinical Trial Site 840423
🇺🇸Everett, Washington, United States
Chiesi Clinical Trial Site 840342
🇺🇸Renton, Washington, United States
Chiesi Clinical Trial Site 840154
🇺🇸Vancouver, Washington, United States
Chiesi Clinical Trial Site 840421
🇺🇸Kingwood, West Virginia, United States
Chiesi Clinical Trial Site 840201
🇺🇸Morgantown, West Virginia, United States
Chiesi Clinical Trial Site 032115
🇦🇷Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032113
🇦🇷Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032107
🇦🇷Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032112
🇦🇷Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032121
🇦🇷Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032110
🇦🇷Florencio Varela, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032108
🇦🇷La Plata, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032118
🇦🇷Mar Del Plata, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032114
🇦🇷Mar Del Plata, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032102
🇦🇷Monte Grande, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032106
🇦🇷Quilmes, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032116
🇦🇷San Fernando, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032100
🇦🇷Vicente López, Buenos Aires, Argentina
Chiesi Clinical Trial Site 032111
🇦🇷Córdoba, Cordoba, Argentina
Chiesi Clinical Trial Site 100115
🇧🇬Montana, Bulgaria
Chiesi Clinical Trial Site 032120
🇦🇷Concepción Del Uruguay, Entre Rios, Argentina
Chiesi Clinical Trial Site 032101
🇦🇷Rosario, Santa Fe, Argentina
Chiesi Clinical Trial Site 032132
🇦🇷Rosario, Santa Fe, Argentina
Chiesi Clinical Trial Site 032117
🇦🇷Tucumán, Tucuman, Argentina
Chiesi Clinical Trial Site 032125
🇦🇷Buenos Aires, Argentina
Chiesi Clinical Trial Site 032130
🇦🇷Buenos Aires, Argentina
Chiesi Clinical Trial Site 032133
🇦🇷Buenos Aires, Argentina
Chiesi Clinical Trial Site 032103
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Chiesi Clinical Trial Site 032109
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Chiesi Clinical Trial Site 032105
🇦🇷Mendoza, Argentina
Chiesi Clinical Trial Site 032123
🇦🇷Paraná, Argentina
Chiesi Clinical Trial Site 032128
🇦🇷Rosario, Argentina
Chiesi Clinical Trial Site 032134
🇦🇷San Miguel De Tucumán, Argentina
Chiesi Clinical Trial Site 032122
🇦🇷Córdoba, Argentina
Chiesi Clinical Trial Site 032131
🇦🇷Lobos, Argentina
Chiesi Clinical Trial Site 032119
🇦🇷Mar Del Plata, Argentina
Chiesi Clinical Trial Site 032129
🇦🇷Mendoza, Argentina
Chiesi Clinical Trial Site 032126
🇦🇷Mendoza, Argentina
Chiesi Clinical Trial Site 032136
🇦🇷San Miguel De Tucumán, Argentina
Chiesi Clinical Trial Site 032127
🇦🇷San Rafael, Argentina
Chiesi Clinical Trial Site 100125
🇧🇬Gabrovo, Bulgaria
Chiesi Clinical Trial Site 100129
🇧🇬Kozloduy, Bulgaria
Chiesi Clinical Trial Site 032124
🇦🇷Santa Fe, Argentina
Chiesi Clinical Trial Site 100109
🇧🇬Haskovo, Bulgaria
Chiesi Clinical Trial Site 100131
🇧🇬Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100104
🇧🇬Ruse, Bulgaria
Chiesi Clinical Trial Site 100102
🇧🇬Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100126
🇧🇬Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100128
🇧🇬Razgrad, Bulgaria